Drug Profile
ATON 009
Alternative Names: ATON-009Latest Information Update: 19 Jul 2018
Price :
$50
*
At a glance
- Originator Aton Pharma
- Class Antidotes
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Poisoning
Most Recent Events
- 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
- 16 Jul 2016 No recent reports of development identified for phase-I development in Poisoning in USA
- 27 Jan 2011 Phase-I clinical trials in Poisoning in USA (unspecified route)